SCHEMBL19743059

SCHEMBL19743059

Nc1c(S(=O)(=O)c2ccccc2F)c2nccnc2n1C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 11/20 0.47
HTR6 P50406 3/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
GAA P10253 2/20 0.43
MAPK1 P28482 1/20 0.37
NPY1R P25929 1/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
HPGD P15428 1/20 0.35
DNMT1 P26358 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
PLEC Q15149 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTR2A P28223 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17378947 0.84 KDM4E (0.61) FFAR2HTR6KDM4EALDH1A1GAA
SCHEMBL17378999 0.82 KDM4E (0.47) FFAR2HTR6KDM4EALDH1A1GAA
SCHEMBL19743036 0.82 HTR6 (0.40) FFAR2HTR6KDM4EALDH1A1GAA
SCHEMBL19743068 0.81 FFAR2 (0.48) FFAR2HTR6KDM4EALDH1A1GAA
SCHEMBL19742984 0.81 KDM4E (0.62) FFAR2HTR6KDM4EALDH1A1GAA
SCHEMBL17378997 0.78 ALDH1A1 (0.45) KDM4EALDH1A1GAAMAPK1MEN1
SCHEMBL17378958 0.78 ALDH1A1 (0.47) FFAR2HTR6KDM4EALDH1A1GAA
SCHEMBL19743039 0.78 ALDH1A1 (0.40) HTR6KDM4EALDH1A1GAAMAPK1
SCHEMBL17378957 0.78 KDM4E (0.47) FFAR2KDM4EALDH1A1GAAMAPK1
SCHEMBL17378959 0.78 KDM4E (0.47) FFAR2KDM4EALDH1A1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US claimed
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US disclosed
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE GPR119, IDO1, IDO2 FFAR2 380/4885HTR6 28/4885KDM4E 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.